Tumor Biology

, Volume 34, Issue 4, pp 2225–2231 | Cite as

CYP2E1 T7632A and 9-bp insertion polymorphisms and colorectal cancer risk: a meta-analysis based on 4,592 cases and 5,918 controls

  • Jun Qian
  • Zhangfa Song
  • Yinxiang Lv
  • Xuefeng Huang
Research Article

Abstract

Previous studies suggest that genetic factors play important roles in the development of colorectal cancer. CYP2E1 T7632A and 9-bp insertion polymorphisms may influence the risk of colorectal cancer, but published results are conflicting. We therefore conducted a meta-analysis comprising 9 case–control studies with 4,592 cases and 5,918 controls. Odds ratios (ORs) with 95 % confidence interval (95 % CI) were used to assess the strength of the associations of CYP2E1 T7632A and 9-bp insertion polymorphisms with colorectal cancer. For CYP2E1 T7632A polymorphism, meta-analysis showed that there was no significant association between the CYP2E1 T7632A polymorphism and colorectal cancer risk under all contrast models (A vs. T: OR = 1.06, 95 % CI 0.88–1.29, P = 0.528; AA vs. TT: OR = 0.85, 95 % CI 0.61–1.19, P = 0.351; AA/TA vs. TT: OR = 1.08, 95 % CI 0.87–1.34, P = 0.484; and AA vs. TT/TA: OR = 0.87, 95 % CI 0.62–1.21, P = 0.395). For CYP2E1 96-bp insertion polymorphism, meta-analysis showed that there was a significant association between the CYP2E1 96-bp insertion polymorphism and colorectal cancer risk under the allele contrast model and the dominant contrast model (for the allele contrast model: OR = 1.20, 95 % CI 1.06–1.36, P = 0.005; for the dominant contrast model: OR = 1.25, 95 % CI 1.07–1.45, P = 0.005). Subgroup analysis by race suggested that there was an obvious association between the CYP2E1 96-bp insertion polymorphism and colorectal cancer risk in Asians under the codominant contrast model. In conclusion, our meta-analysis demonstrates that there is a significant association between the CYP2E1 96-bp insertion polymorphism and colorectal cancer risk, and CYP2E1 9-bp insertion polymorphism is a risk factor for developing colorectal cancer.

Keywords

CYP2E1 Polymorphism Colorectal cancer Meta-analysis 

Notes

Conflict of interest

The authors declare no any conflicts of interest in this research.

References

  1. 1.
    Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–78.PubMedCrossRefGoogle Scholar
  2. 2.
    Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010;375:1030–47.PubMedCrossRefGoogle Scholar
  3. 3.
    Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479–507.PubMedCrossRefGoogle Scholar
  5. 5.
    Kennedy DA, Stern SJ, Matok I, Moretti ME, Sarkar M, Adams-Webber T, et al. Folate intake, MTHFR polymorphisms, and the risk of colorectal cancer: a systematic review and meta-analysis. J Cancer Epidemiol. 2012;2012:952508.PubMedGoogle Scholar
  6. 6.
    Zeng FR, Ling Y, Yang J, Tian XC, Yang X, Luo RC. X-ray repair cross-complementing group 1 ARG399GLN gene polymorphism and susceptibility to colorectal cancer: a meta-analysis. Tumour Biol. 2013;34:555–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Caro AA, Cederbaum AI. Oxidative stress, toxicology, and pharmacology of cyp2e1. Annu Rev Pharmacol Toxicol. 2004;44:27–42.PubMedCrossRefGoogle Scholar
  8. 8.
    Miksys S, Tyndale RF. The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab Rev. 2004;36:313–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Daly AK. Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects. Adv Pharmacol. 2012;63:137–67.PubMedCrossRefGoogle Scholar
  10. 10.
    Huang X, Chen L, Song W, Niu J, Han X, Feng G, et al. Systematic functional characterization of cytochrome P450 2E1 promoter variants in the chinese han population. PLoS One. 2012;7:e40883.PubMedCrossRefGoogle Scholar
  11. 11.
    Zhuo W, Zhang L, Wang Y, Ling J, Zhu B, Chen Z. CYP2E1 Rsai/PstI polymorphism and gastric cancer susceptibility: meta-analyses based on 24 case–control studies. PLoS One. 2012;7:e48265.PubMedCrossRefGoogle Scholar
  12. 12.
    Le Marchand L, Donlon T, Seifried A, Wilkens LR. Red meat intake, CYP2E1 genetic polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1019–24.PubMedGoogle Scholar
  13. 13.
    van der Logt EM, Bergevoet SM, Roelofs HM, Te Morsche RH, Dijk Y, Wobbes T, et al. Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer. Mutat Res. 2006;593:39–49.PubMedCrossRefGoogle Scholar
  14. 14.
    Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey AB, Harper PA. Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:3098–107.PubMedCrossRefGoogle Scholar
  15. 15.
    Cleary SP, Cotterchio M, Shi E, Gallinger S, Harper P. Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. Am J Epidemiol. 2010;172:1000–14.PubMedCrossRefGoogle Scholar
  16. 16.
    Morita M, Le Marchand L, Kono S, Yin G, Toyomura K, Nagano J, et al. Genetic polymorphisms of CYP2E1 and risk of colorectal cancer: the Fukuoka colorectal cancer study. Cancer Epidemiol Biomarkers Prev. 2009;18:235–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Darazy M, Balbaa M, Mugharbil A, Saeed H, Sidani H, Abdel-Razzak Z. CYP1A1, CYP2E1, and GSTM1 gene polymorphisms and susceptibility to colorectal and gastric cancer among Lebanese. Genet Test Mol Biomarkers. 2011;15:423–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Sameer AS, Nissar S, Qadri Q, Alam S, Baba SM, Siddiqi MA. Role of CYP2E1 genotypes in susceptibility to colorectal cancer in the Kashmiri population. Hum Genomics. 2011;5:530–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Silva TD, Felipe AV, Pimenta CA, Barao K, Forones NM. CYP2E1 Rsai and 96-bp insertion genetic polymorphisms associated with risk for colorectal cancer. Genet Mol Res. 2012;11:3138–45.PubMedCrossRefGoogle Scholar
  20. 20.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  21. 21.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  22. 22.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  23. 23.
    Yang H, Cao J. Genetic association study between polymorphisms of major alcohol metabolizing and JWA genes and colorectal cancer. Wanfang Doctoral Dissertation 2009; The Third Military Medical University.Google Scholar
  24. 24.
    Huo R, Tang K, Wei Z, Shen L, Xiong Y, Wu X, et al. Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population. PLoS One. 2012;7:e34809.PubMedCrossRefGoogle Scholar
  25. 25.
    Hiratsuka M. In vitro assessment of the allelic variants of cytochrome p450. Drug Metab Pharmacokinet. 2012;27:68–84.PubMedCrossRefGoogle Scholar
  26. 26.
    Neafsey P, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B. Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity. J Toxicol Environ Health B Crit Rev. 2009;12:362–88.PubMedCrossRefGoogle Scholar
  27. 27.
    Boccia S, De Lauretis A, Gianfagna F, van Duijn CM, Ricciardi G. CYP2E1Psti/RsaI polymorphism and interaction with tobacco, alcohol and GSTs in gastric cancer susceptibility: a meta-analysis of the literature. Carcinogenesis. 2007;28:101–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Liu C, Wang H, Pan C, Shen J, Liang Y. CYP2E1 Psti/RsaI polymorphism and interaction with alcohol consumption in hepatocellular carcinoma susceptibility: evidence from 1,661 cases and 2,317 controls. Tumour Biol. 2012;33:979–84.PubMedCrossRefGoogle Scholar
  29. 29.
    Wang Y, Yang H, Li L, Wang H, Zhang C, Yin G, et al. Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis. Eur J Cancer. 2010;46:758–64.PubMedCrossRefGoogle Scholar
  30. 30.
    Niu Y, Hu Y, Wu M, Jiang F, Shen M, Tang C, et al. CYP2E1 Rsa i/Pst I polymorphism contributes to oral cancer susceptibility: a meta-analysis. Mol Biol Rep. 2012;39:607–12.PubMedCrossRefGoogle Scholar
  31. 31.
    Niu Y, Yuan H, Leng W, Pang Y, Gu N, Chen N. CYP2E1 Rsa i/Pst I polymorphism and esophageal cancer risk: a meta-analysis based on 1,088 cases and 2,238 controls. Med Oncol. 2011;28:182–7.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Jun Qian
    • 1
  • Zhangfa Song
    • 2
  • Yinxiang Lv
    • 1
  • Xuefeng Huang
    • 2
  1. 1.Department of Colorectal SurgeryXinchang People’s HospitalXinchangChina
  2. 2.Department of Colorectal Surgery, Sir Run Run Shaw HospitalZhejiang UniversityHangzhouChina

Personalised recommendations